The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Holistic approach to CLL management
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, talks on using a holistic approach to the treatment and management of chronic lymphocytic leukemia (CLL), highlighting the impacts of novel therapies on the treatment landscape and the importance of improving the quality of life of patients with CLL. Dr Ghia describes how many factors need to be considered in the management of patients with CLL, including practical considerations, comorbidities and genetic factors which may impact outcomes to therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
